PROG
Income statement / Annual
Last year (2023), Biora Therapeutics, Inc.'s total revenue was $4,000.00,
a decrease of 98.69% from the previous year.
In 2023, Biora Therapeutics, Inc.'s net income was -$124.12 M.
See Biora Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$4,000.00
|
$305,000.00
|
$1.25 M
|
$74.31 M
|
$143.99 M
|
$127.97 M
|
| Cost of Revenue |
$0.00 |
$907,000.00 |
$1.44 M |
$93.43 M |
$100.49 M |
$92.08 M |
| Gross Profit |
$4,000.00 |
-$602,000.00 |
-$190,000.00 |
-$19.12 M |
$43.49 M |
$35.90 M |
| Gross Profit Ratio |
1 |
-1.97 |
-0.15 |
-0.26 |
0.3 |
0.28 |
| Research and Development
Expenses |
$29.84 M
|
$24.05 M
|
$45.79 M
|
$47.74 M
|
$63.40 M
|
$48.71 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$68.54 M
|
$75.44 M
|
$61.32 M
|
$51.24 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$4.76 M
|
$52.89 M
|
$58.89 M
|
$50.19 M
|
| Selling, General &
Administrative Expenses |
$37.31 M
|
$38.04 M
|
$73.30 M
|
$128.33 M
|
$120.21 M
|
$101.43 M
|
| Other Expenses |
$0.00 |
$2.62 M |
$5.99 M |
-$25.08 M |
$0.00 |
$0.00 |
| Operating Expenses |
$67.15 M |
$62.09 M |
$119.08 M |
$176.07 M |
$183.61 M |
$150.14 M |
| Cost And Expenses |
$67.15 M |
$62.09 M |
$119.08 M |
$269.50 M |
$284.10 M |
$242.21 M |
| Interest Income |
$0.00 |
$10.99 M |
$12.64 M |
$9.92 M |
$575,000.00 |
$1.80 M |
| Interest Expense |
$9.82 M |
$10.99 M |
$12.64 M |
$34.87 M |
$9.20 M |
$9.09 M |
| Depreciation &
Amortization |
$555,000.00
|
$907,000.00
|
$1.44 M
|
$1.44 M
|
$4.60 M
|
$4.60 M
|
| EBITDA |
-$114.05 M
|
-$37.35 M
|
-$164.57 M
|
-$106.18 M
|
-$135.44 M
|
-$110.17 M
|
| EBITDA Ratio |
-28513.5 |
-193.98 |
-51.07 |
-2.63 |
-0.93 |
-0.85 |
| Operating Income Ratio
|
-16785.75
|
-202.56
|
-94.5
|
-2.63
|
-0.97
|
-0.89
|
| Total Other
Income/Expenses Net |
-$57.28 M
|
$12.53 M
|
-$60.80 M
|
-$35.00 M
|
-$8.62 M
|
-$9.62 M
|
| Income Before Tax |
-$124.42 M |
-$49.25 M |
-$178.64 M |
-$230.06 M |
-$148.74 M |
-$123.86 M |
| Income Before Tax Ratio
|
-31106
|
-161.48
|
-143.26
|
-3.1
|
-1.03
|
-0.97
|
| Income Tax Expense |
-$90,000.00 |
-$420,000.00 |
-$119,000.00 |
-$37.53 M |
-$706,000.00 |
$5.25 M |
| Net Income |
-$124.12 M |
-$48.83 M |
-$178.52 M |
-$192.53 M |
-$148.04 M |
-$129.11 M |
| Net Income Ratio |
-31028.75 |
-160.1 |
-143.16 |
-2.59 |
-1.03 |
-1.01 |
| EPS |
-7.87 |
-6.4 |
-46.42 |
-86.3 |
-80.17 |
-119.71 |
| EPS Diluted |
-7.87 |
-6.4 |
-46.42 |
-86.3 |
-80.17 |
-119.71 |
| Weighted Average Shares
Out |
$15.77 M
|
$7.64 M
|
$3.85 M
|
$2.23 M
|
$1.85 M
|
$1.08 M
|
| Weighted Average Shares
Out Diluted |
$15.77 M
|
$7.64 M
|
$3.85 M
|
$2.23 M
|
$1.85 M
|
$1.08 M
|
| Link |
|
|
|
|
|
|
